Agenus Income Statement

Health Care & Life Sciences » Biotechnology | Agenus Inc.

Agenus Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.

2013

2014

2015

2016

2017

2018

Sales/Revenue

3,045.20

6,977.50

24,817.00

22,573.30

42,877.10

36,783.60

Cost of Goods Sold (COGS) incl. D&A

829.30

1,584.00

1,957.60

Gross Income

2,215.90

5,393.50

22,859.40

SG&A Expense

27,196.00

42,015.10

83,656.70

123,149.30

143,860.20

155,652.10

EBIT

24,980.10

36,621.60

60,797.20

105,523.80

106,989.40

125,156.60

Unusual Expense

3,614.20

3,579.30

26,920.80

1,953.00

3,188.00

9,431.60

Non Operating Income/Expense

941.40

1,023.70

1,049.00

2,202.30

1,977.40

2,183.30

Interest Expense

2,427.70

1,261.60

6,599.10

17,316.10

18,868.50

25,272.60

Pretax Income

30,072.70

42,486.20

93,268.20

126,995.20

120,692.50

162,044

Income Tax

5,387.10

Consolidated Net Income

30,072.70

42,486.20

87,881.10

126,995.20

120,692.50

162,044

Net Income

30,072.70

42,486.20

87,881.10

126,995.20

120,692.50

159,692.10

Net Income After Extraordinaries

30,072.70

42,486.20

87,881.10

126,995.20

120,692.50

159,692.10

Net Income Available to Common

33,232.50

42,690.00

88,084.10

127,199.40

120,898.00

159,899

EPS (Basic)

1.12

0.71

1.13

1.46

1.23

1.44

Basic Shares Outstanding

29,765.50

59,753.60

78,212.10

87,070.20

98,415.40

110,772.30

EPS (Diluted)

1.12

0.71

1.13

1.46

1.23

1.44

Diluted Shares Outstanding

29,765.50

59,753.60

78,212.10

87,070.20

98,415.40

110,772.30

EBITDA

24,393.80

35,037.60

58,839.60

100,576.00

100,983.10

118,868.60

Non-Operating Interest Income

7.90

Preferred Dividends

3,159.80

203.80

203.00

204.20

205.50

206.80

About Agenus

View Profile

Address	3 Forbes Road Lexington Massachusetts 02421 United States
Employees	-
Website	http://www.agenusbio.com
Updated	07/08/2019
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, Next-gen CTLA-A, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H.

Agenus Inc. | Income Statement

About Agenus

StatInvestor